1375A 7th Avenue
San Francisco, CA 94122
Empire Biotechnologies is developing an orally delivered, protein therapeutic called Mfge8 to treat diseases of malabsorption. Our long-term vision is a therapy for the millions suffering from malabsorption; our current focus is the orphan disease Short Bowel Syndrome (SBS). SBS patients suffer from debilitating malnutrition, and treatments are extremely limited, demonstrating a significant unmet need.